NEW YORK, Feb. 8, 2018 /PRNewswire-USNewswire/ — The U.S. Judicial Panel on Multidistrict Litigation (JPML) has ordered all federally-filed product liability lawsuits involving Onglyza and Kombiglyze XR to be centralized before a single judge in the U.S. District Court, Eastern District of Kentucky. (IN RE: ONGLYZA (SAXAGLIPTIN) AND KOMBIGLYZE XR (SAXAGLIPTIN AND METFORMIN) PRODUCTS LIABILITY LITIGATION, MDL No. 2809)
Court documents indicate that more than 80 such claims are currently pending in 30 federal jurisdictions, all of which were filed on behalf of individuals who experienced heart failure and other cardiovascular injuries allegedly due to side effects associated with saxagliptin, the active ingredient in Onglyza and Kombiglyze XR. In agreeing to consolidate the docket, the JPML noted that all of the pending cases involve common questions of fact, and asserted that centralization will “serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation.”
“Our Firm has heard from numerous individuals who allegedly suffered heart failure or other cardiac problems due to saxagliptin, and we continue to receive such inquiries on a regular basis. The litigation involving Onglyza and Kombiglyze XR could grow to include hundreds of similar lawsuits, warranting centralization before a single judge,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free legal reviews to individuals who were diagnosed with heart failure following treatment with Onglyza or Kombiglyze XR.
Saxagliptin and Heart Failure
Onglyza and Kombiglyze XR are indicated to lower blood sugar levels in patients with Type 2 diabetes. Onglyza (saxagliptin) was approved by the U.S. Food & Drug Administration (FDA) in 2009, while Kombiglyze XR (saxagliptin and metformin) was cleared for sale in November 2010.
In April 2015, a panel of outside FDA advisers recommended that the prescribing information for saxagliptin-containing medications be updated to include heart failure as a possible side effect, after a clinical trial called SAVOR-TMI suggested that the medications were associated with a 27% increase in hospitalizations for heart failure, as well as a higher risk of all-cause mortality The FDA ordered the drugs’ manufacturers to modify the labels’ “Warnings and Precautions” section to reflect these findings in April 2016.
The JPML’s decision to centralize all federally-filed Onglyza and Kombiglyze XR lawsuits in the Eastern District of Kentucky will allow the pending claims, as well as any filed in the future, to undergo coordinated discovery and other pretrial proceedings. Centralization is intended to eliminate duplicative discovery; prevent inconsistent pretrial rulings; and conserve the resources of the parties, their attorneys, and the courts.
Type 2 diabetes patients who were diagnosed with heart failure while using Onglyza or Kombiglyze XR could be entitled to compensation for medical bills, lost wages, pain and suffering and more. For a free case review, please visit Bernstein Liebhard LLP’s website, or call the Firm directly at 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal’s “Plaintiffs’ Hot List,” recognizing the top plaintiffs firms in the country. This year’s nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
SOURCE Bernstein Liebhard LLP